The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification.

By Rishika Sadam HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as ...

Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the Institutional Review Board (IRB) at Clinical Pharmacology ...

Ever since weight loss drugs hit the market, their sky-high price has pushed them out of reach for most patients, but that is about to change. Within days, millions are set to gain access to Ozempic ...

NASDAQ: MTVA Lili Elston: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host, Zacks Small Cap Research, we're very pleased you've joined us. The next ...

The drug’s efficacy “looks to be highly competitive” and potentially better than rival pills from Novo and Lilly, BMO Capital ...

A 40–50% price drop in GLP-1 weight-loss drugs like Ozempic could boost access in India. Experts weigh in on benefits, risks, and rising demand.

SANTA ANA, CA - March 16, 2026 - PRESSADVANTAGE - Moment of Clarity has published a new educational resource detailing ...

Dr. Austin Harris, a board-certified cardiothoracic anesthesiologist and the founder of NeuroRelief Ketamine & Infusion Therapy, is redefining the treatment landscape for patients grappling with ...

The launch of Cloudcure's companion app marks the first step in the company's broader roadmap that will introduce additional clinical and technological capabilities. The company is developing features ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...